Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer

Bibliography

• Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000;57:1050-93
   PubMed Web of Science ®Google Scholar
• De Meyts P. The insulin receptor: a prototype for dimeric, allosteric membrane receptors? Trends Biochem Sci 2008;33:376-84
   PubMed Web of Science ®Google Scholar
• De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002;1:769-83
   PubMed Web of Science ®Google Scholar
• Lawrence MC, McKern NM, Ward CW. Insulin receptor structure and its implications for the IGF-1 receptor. Curr Opin Struct Biol 2007;17:699-705
   PubMed Web of Science ®Google Scholar
• Ward CW, Garrett TP, McKern NM, The three dimensional structure of the type I insulin-like growth factor receptor. Mol Pathol 2001;54:125-32
   PubMedGoogle Scholar
• Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002;110:669-72
   PubMed Web of Science ®Google Scholar
• Favelyukis S, Till JH, Hubbard SR, Miller WT. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001;8:1058-63
   PubMedGoogle Scholar
• Denley A, Wallace JC, Cosgrove LJ, Forbes BE. The insulin receptor isoform exon 11- (IR-A) in cancer and other diseases: a review. Horm Metab Res 2003;35:778-85
   PubMed Web of Science ®Google Scholar
• Mosthaf L, Grako K, Dull TJ, Functionally distinct insulin receptors generated by tissue-specific alternative splicing. Embo J 1990;9:2409-13
   PubMed Web of Science ®Google Scholar
• Belfiore A, Frasca F, Pandini G, Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623
   PubMed Web of Science ®Google Scholar
• Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993;75:73-82
   PubMed Web of Science ®Google Scholar
• Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol 1997;189:33-48
   PubMed Web of Science ®Google Scholar
• Morrione A, Valentinis B, Xu SQ, Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc Natl Acad Sci USA 1997;94:3777-82
   PubMed Web of Science ®Google Scholar
• Frasca F, Pandini G, Scalia P, Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999;19:3278-88
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Flier JS, Yokota A, Functional properties of two naturally occurring isoforms of the human insulin receptor in Chinese hamster ovary cells. Endocrinology 1991;129:2058-66
   PubMed Web of Science ®Google Scholar
• Adams TE, McKern NM, Ward CW. Signalling by the type 1 insulin-like growth factor receptor: interplay with the epidermal growth factor receptor. Growth Factors 2004;22:89-95
   PubMed Web of Science ®Google Scholar
• Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Curr Pharm Des 2007;13:663-9
   PubMed Web of Science ®Google Scholar
• LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-37
   PubMed Web of Science ®Google Scholar
• Peruzzi F, Prisco M, Dews M, Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 1999;19:7203-15
   PubMed Web of Science ®Google Scholar
• Ceresa BP, Pessin JE. Insulin regulation of the Ras activation/inactivation cycle. Mol Cell Biochem 1998;182:23-9
   PubMed Web of Science ®Google Scholar
• Cui H, Cruz-Correa M, Giardiello FM, Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-5
   PubMed Web of Science ®Google Scholar
• Rainier S, Johnson LA, Dobry CJ, Relaxation of imprinted genes in human cancer. Nature 1993;362:747-9
   PubMed Web of Science ®Google Scholar
• Steenman MJ, Rainier S, Dobry CJ, Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour. Nat Genet 1994;7:433-9
   PubMed Web of Science ®Google Scholar
• Clemmons DR. Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 1997;8:45-62
   PubMedGoogle Scholar
• Stoger R, Kubicka P, Liu CG, Maternal-specific methylation of the imprinted mouse Igf2r locus identifies the expressed locus as carrying the imprinting signal. Cell 1993;73:61-71
   PubMed Web of Science ®Google Scholar
• Liu JP, Baker J, Perkins AS, Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008;8:915-28
   PubMed Web of Science ®Google Scholar
• Sell C, Rubini M, Rubin R, Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc Natl Acad Sci USA 1993;90:11217-21
   PubMed Web of Science ®Google Scholar
• Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 2008;68:8322-32
   PubMed Web of Science ®Google Scholar
• Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 2008;14:6730-4
   PubMed Web of Science ®Google Scholar
• Cohen BD, Baker DA, Soderstrom C, Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11:2063-73
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Pearson MA, Marti A, In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004;5:231-9
   PubMed Web of Science ®Google Scholar
• Maloney EK, McLaughlin JL, Dagdigian NE, An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003;63:5073-83
   PubMed Web of Science ®Google Scholar
• Chan JM, Stampfer MJ, Giovannucci E, Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998;279:563-6
   PubMed Web of Science ®Google Scholar
• Hankinson SE, Willett WC, Colditz GA, Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-6
   PubMed Web of Science ®Google Scholar
• Ma J, Pollak MN, Giovannucci E, Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-5
   PubMed Web of Science ®Google Scholar
• Chen CL, Ip SM, Cheng D, Loss of imprinting of the IGF-II and H19 genes in epithelial ovarian cancer. Clin Cancer Res 2000;6:474-9
   PubMed Web of Science ®Google Scholar
• Fottner C, Hoeflich A, Wolf E, Weber MM. Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm Metab Res 2004;36:397-405
   PubMed Web of Science ®Google Scholar
• Giordano TJ, Kuick R, Else T, Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009;15:668-76
   PubMed Web of Science ®Google Scholar
• Nonomura N, Nishimura K, Miki T, Loss of imprinting of the insulin-like growth factor II gene in renal cell carcinoma. Cancer Res 1997;57:2575-7
   PubMed Web of Science ®Google Scholar
• Wang Z, Ruan YB, Guan Y, Liu SH. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol 2003;9:267-70
   PubMed Web of Science ®Google Scholar
• Accili D. Molecular defects of the insulin receptor gene. Diabetes Metab Rev 1995;11:47-62
   PubMed Web of Science ®Google Scholar
• Wertheimer E, Spravchikov N, Trebicz M, The regulation of skin proliferation and differentiation in the IR null mouse: implications for skin complications of diabetes. Endocrinology 2001;142:1234-41
   PubMed Web of Science ®Google Scholar
• Fulzele K, DiGirolamo DJ, Liu Z, Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem 2007;282:25649-58
   PubMed Web of Science ®Google Scholar
• Frittitta L, Vigneri R, Stampfer MR, Goldfine ID. Insulin receptor overexpression in 184B5 human mammary epithelial cells induces a ligand-dependent transformed phenotype. J Cell Biochem 1995;57:666-9
   PubMed Web of Science ®Google Scholar
• Giorgino F, Belfiore A, Milazzo G, Overexpression of insulin receptors in fibroblast and ovary cells induces a ligand-mediated transformed phenotype. Mol Endocrinol 1991;5:452-9
   PubMed Web of Science ®Google Scholar
• Kalli KR, Falowo OI, Bale LK, Functional insulin receptors on human epithelial ovarian carcinoma cells: implications for IGF-II mitogenic signaling. Endocrinology 2002;143:3259-67
   PubMed Web of Science ®Google Scholar
• Vella V, Pandini G, Sciacca L, A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 2002;87:245-54
   PubMed Web of Science ®Google Scholar
• Sciacca L, Prisco M, Wu A, Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology 2003;144:2650-8
   PubMed Web of Science ®Google Scholar
• Sciacca L, Costantino A, Pandini G, Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999;18:2471-9
   PubMed Web of Science ®Google Scholar
• Buck E, Gokhale P, Koujak S, Compensatory insulin receptor (IR) activation upon inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for co-targeting IGF-1R and IR in cancer. Mol Cancer Ther 2010;9:2652-64
   PubMed Web of Science ®Google Scholar
• Heuson JC, Legros N. Effect of insulin and of alloxan diabetes on growth of the rat mammary carcinoma in vivo. Eur J Cancer 1970;6:349-51
   PubMed Web of Science ®Google Scholar
• Pavelic K, Pavelic Z, Poljak-Blazi M, Sverko V. The effect of insulin on the growth of transplanted tumors in mice. Biomedicine 1979;31:125-7
   PubMedGoogle Scholar
• Saito K, Inoue S, Saito T, Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002;51:100-4
   PubMed Web of Science ®Google Scholar
• Giovannucci E. Insulin and colon cancer. Cancer Causes Control 1995;6:164-79
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin-like growth factor physiology and neoplasia. Growth Horm IGF Res 2000;10(Suppl A):S6-7
   PubMedGoogle Scholar
• Gunter MJ, Hoover DR, Yu H, Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 2008;68:329-37
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Hoover DR, Yu H, Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48-60
   PubMed Web of Science ®Google Scholar
• Jenab M, Riboli E, Cleveland RJ, Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition. Int J Cancer 2007;121:368-76
   PubMed Web of Science ®Google Scholar
• Ma J, Giovannucci E, Pollak M, A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-53
   PubMed Web of Science ®Google Scholar
• Kling J. Inhaled insulin's last gasp? Nat Biotechnol 2008;26:479-80
   PubMed Web of Science ®Google Scholar
• Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 2008;8:384-92
   PubMed Web of Science ®Google Scholar
• Guix M, Faber AC, Wang SE, Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008;118:2609-19
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005;65:11118-28
   PubMed Web of Science ®Google Scholar
• O'Reilly KE, Rojo F, She QB, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8
   PubMed Web of Science ®Google Scholar
• Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol 2006;16:59-64
   PubMed Web of Science ®Google Scholar
• Cosaceanu D, Budiu RA, Carapancea M, Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism. Oncogene 2007;26:2423-34
   PubMed Web of Science ®Google Scholar
• Iwasa T, Okamoto I, Suzuki M, Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 2009;15:5117-25
   PubMed Web of Science ®Google Scholar
• Wang YH, Wang ZX, Qiu Y, Lentivirus-mediated RNAi knockdown of insulin-like growth factor-1 receptor inhibits growth, reduces invasion, and enhances radiosensitivity in human osteosarcoma cells. Mol Cell Biochem 2009;327:257-66
   PubMed Web of Science ®Google Scholar
• Allen GW, Saba C, Armstrong EA, Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007;67:1155-62
   PubMed Web of Science ®Google Scholar
• Zeng X, Sachdev D, Zhang H, Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res 2009;15:2840-9
   PubMed Web of Science ®Google Scholar
• Martins AS, Mackintosh C, Martin DH, Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006;12:3532-40
   PubMed Web of Science ®Google Scholar
• Miglietta A, Panno ML, Bozzo F, Insulin can modulate MCF-7 cell response to paclitaxel. Cancer Lett 2004;209:139-45
   PubMed Web of Science ®Google Scholar
• Dunn SE, Ehrlich M, Sharp NJ, A dominant negative mutant of the insulin-like growth factor-I receptor inhibits the adhesion, invasion, and metastasis of breast cancer. Cancer Res 1998;58:3353-61
   PubMed Web of Science ®Google Scholar
• Eyzaguirre A, Pachter JA, Haley JD, OSI-906, a small molecule kinase inhibitor of IGF-1R, sensitizes tumor cells to the cytotoxic effects of chemotherapeutic agents by blocking survival pathways [abstract #4014]. Proceedings of the 100th Annual Meeting of the American Association for Cancer Research 2009
   Google Scholar
• Liu YF, Herschkovitz A, Boura-Halfon S, Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate 1 function and promotes insulin resistance. Mol Cell Biol 2004;24:9668-81
   PubMed Web of Science ®Google Scholar
• Paz K, Hemi R, LeRoith D, A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. J Biol Chem 1997;272:29911-8
   PubMed Web of Science ®Google Scholar
• Law JH, Habibi G, Hu K, Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 2008;68:10238-46
   PubMed Web of Science ®Google Scholar
• Monti S, Proietti-Pannunzi L, Sciarra A, The IGF axis in prostate cancer. Curr Pharm Des 2007;13:719-27
   PubMed Web of Science ®Google Scholar
• Zhang X, Yee D. Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res 2000;2:170-5
   PubMed Web of Science ®Google Scholar
• Ma J, Giovannucci E, Pollak M, A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004;96:546-53
   PubMed Web of Science ®Google Scholar
• Song RX, Santen RJ, Kumar R, Adaptive mechanisms induced by long-term estrogen deprivation in breast cancer cells. Mol Cell Endocrinol 2002;193:29-42
   PubMed Web of Science ®Google Scholar
• Masamura S, Santner SJ, Heitjan DF, Santen RJ. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918-25
   PubMed Web of Science ®Google Scholar
• Song RX, Barnes CJ, Zhang Z, The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci USA 2004;101:2076-81
   PubMed Web of Science ®Google Scholar
• Song RX, McPherson RA, Adam L, Linkage of rapid estrogen action to MAPK activation by ERalpha–Shc association and Shc pathway activation. Mol Endocrinol 2002;16:116-27
   PubMed Web of Science ®Google Scholar
• Song RX, Fan P, Yue W, Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. Endocr Relat Cancer 2006;13(Suppl 1):S3-13
   PubMedGoogle Scholar
• Ignar-Trowbridge DM, Teng CT, Ross KA, Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 1993;7:992-8
   PubMed Web of Science ®Google Scholar
• Lee AV, Weng CN, Jackson JG, Yee D. Activation of estrogen receptor-mediated gene transcription by IGF-I in human breast cancer cells. J Endocrinol 1997;152:39-47
   PubMed Web of Science ®Google Scholar
• Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000;5:107-15
   PubMed Web of Science ®Google Scholar
• Stewart AJ, Westley BR, May FE. Modulation of the proliferative response of breast cancer cells to growth factors by oestrogen. Br J Cancer 1992;66:640-8
   PubMed Web of Science ®Google Scholar
• Swanson SM, Unterman TG. The growth hormone-deficient Spontaneous Dwarf rat is resistant to chemically induced mammary carcinogenesis. Carcinogenesis 2002;23:977-82
   PubMed Web of Science ®Google Scholar
• Thordarson G, Semaan S, Low C, Mammary tumorigenesis in growth hormone deficient spontaneous dwarf rats; effects of hormonal treatments. Breast Cancer Res Treat 2004;87:277-90
   PubMed Web of Science ®Google Scholar
• Chakraborty AK, Welsh A, Digiovanna MP. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines. Breast Cancer Res Treat 2010;120:327-35
   PubMed Web of Science ®Google Scholar
• Lisztwan J, Pornon A, Chen B, The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer. Breast Cancer Res 2008;10:R56
   PubMedGoogle Scholar
• Frittitta L, Vigneri R, Papa V, Structural and functional studies of insulin receptors in human breast cancer. Breast Cancer Res Treat 1993;25:73-82
   PubMed Web of Science ®Google Scholar
• Papa V, Pezzino V, Costantino A, Elevated insulin receptor content in human breast cancer. J Clin Invest 1990;86:1503-10
   PubMed Web of Science ®Google Scholar
• Garcia-Arencibia M, Molero S, Davila N, 17beta-Estradiol transcriptionally represses human insulin receptor gene expression causing cellular insulin resistance. Leuk Res 2005;29:79-87
   PubMed Web of Science ®Google Scholar
• Miller TW, Hennessy BT, Gonzalez-Angulo AM, Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest 2010;120:2406-13
   PubMed Web of Science ®Google Scholar
• Wu JD, Haugk K, Woodke L, Interaction of IGF signaling and the androgen receptor in prostate cancer progression. J Cell Biochem 2006;99:392-401
   PubMed Web of Science ®Google Scholar
• Krueckl SL, Sikes RA, Edlund NM, Increased insulin-like growth factor I receptor expression and signaling are components of androgen-independent progression in a lineage-derived prostate cancer progression model. Cancer Res 2004;64:8620-9
   PubMed Web of Science ®Google Scholar
• Miyake H, Pollak M, Gleave ME. Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models. Cancer Res 2000;60:3058-64
   PubMed Web of Science ®Google Scholar
• Nickerson T, Chang F, Lorimer D, In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001;61:6276-80
   PubMed Web of Science ®Google Scholar
• Plymate SR, Haugk K, Coleman I, An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer. Clin Cancer Res 2007;13:6429-39
   PubMed Web of Science ®Google Scholar
• Xin L, Teitell MA, Lawson DA, Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc Natl Acad Sci USA 2006;103:7789-94
   PubMed Web of Science ®Google Scholar
• Wheeler DL, Huang S, Kruser TJ, Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008;27:3944-56
   PubMed Web of Science ®Google Scholar
• Lu Y, Zi X, Pollak M. Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 2004;108:334-41
   PubMed Web of Science ®Google Scholar
• Haluska P, Carboni JM, TenEyck C, HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 2008;7:2589-98
   PubMed Web of Science ®Google Scholar
• Alami N, Page V, Yu Q, Recombinant human insulin-like growth factor-binding protein 3 inhibits tumor growth and targets the Akt pathway in lung and colon cancer models. Growth Horm IGF Res 2008;18:487-96
   PubMed Web of Science ®Google Scholar
• Jerome L, Alami N, Belanger S, Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 2006;66:7245-52
   PubMed Web of Science ®Google Scholar
• Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21
   PubMed Web of Science ®Google Scholar
• Leong S, Gore L, Benjamin R, A phase I study of R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist given weekly in patients with advanced solid tumors. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications 2007; 22-26 October, 2007; San Francisco, USA
   Google Scholar
• Tolcher AW, Sarantopoulos J, Patnaik A, A phase I pharmacokinetic and pharmacodynamic study of AMG479, a fully human monoclonal antibody to insulin-like growth factor type 1 receptor (IGF-1R). J Clin Oncol 2009;27(34):5800-7
   PubMed Web of Science ®Google Scholar
• Gualberto A. Figitumumab (CP-751,871) for cancer therapy. Expert Opin Biol Ther 2010;10:575-85
   PubMed Web of Science ®Google Scholar
• Olmos D, Postel-Vinay S, Molife LR, Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. The Lancet Oncology 2010;11:129-35
   PubMed Web of Science ®Google Scholar
• Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. Lancet Oncol 2010;11:105-6
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Bianconi M, Maccaroni E, Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther 2010;12:361-71
   PubMedGoogle Scholar
• Carden CP, Frentzas S, Langham M, Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors [abstract #3544]. ASCO 2009 Annual Meeting Proceedings 2009. J Clin Oncol 2009;27(15S):3544
   Google Scholar
• Vasilcanu D, Girnita A, Girnita L, The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004;23:7854-62
   PubMed Web of Science ®Google Scholar
• Vasilcanu R, Vasilcanu D, Rosengren L, Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 2008;27:1629-38
   PubMed Web of Science ®Google Scholar
• Ekman S, Frodin JE, Harmenberg J, Clinical Phase I study with an Insulin-like Growth Factor-1 Receptor Inhibitor: Experiences in patients with squamous non-small cell lung carcinoma. Acta oncologica (Stockholm, Sweden) 2011;50(3):441-7
   Web of Science ®Google Scholar
• Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 2009;1:1153-71
   PubMed Web of Science ®Google Scholar
• Lindsay CR, Chan E, Evans TRJ, Phase I dose escalation of continuous oral dosing of OSI-906, an insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors [abstract # 2559]. ASCO 2009 Annual Meeting Proceedings 2009. J Clin Oncol 2009;27(15s): abstract 2559
   Google Scholar
• Carden CP, Kim ES, Jones RL, Phase 1 study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. ASCO 2010 Annual Meeting Proceedings 2010. Clin Oncol 2010:28(15s): abstract 3016
   Google Scholar
• Evans TRJ, Linsdsay CR, Chan E, Phase 1 dose escalation study of continuous oral dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor (IGF-1R) and insulin receptor (IR), in patients with advanced solid tumors. ASCO 2010 Annual Meeting Proceedings 2010. J Clin Oncol 2010:28(15s): abstract 2531
   Google Scholar
• Gedrich R, Poodru S, Stephens A, Pharmacodynamic biomarkers for OSI-906, an insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor, in cancer patients with advanced solid tumors. Mol Can Ther 2009;(12 Suppl. 1)
   Google Scholar
• Macaulay VM, Middleton MR, Eckhardt SG, Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), in combination with erlotinib (E) in patients with advanced solid tumors. ASCO 2010 Annual Meeting Proceedings 2010
   Google Scholar
• Carboni JM, Wittman M, Yang Z, BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009;8:3341-9
   PubMed Web of Science ®Google Scholar
• Wittman MD, Carboni JM, Yang Z, Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development. J Med Chem 2009;52:7360-3
   PubMed Web of Science ®Google Scholar
• Desai J, Solomon BJ, Davis ID, Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. ASCO 2010 Annual Meeting Proceedings 2010. J Clin Oncol 2010;28(15s): abstract 3104
   Google Scholar
• Blecha JE, Anderson MO, Chow JM, Inhibition of IGF-1R and lipoxygenase by nordihydroguaiaretic acid (NDGA) analogs. Bioorg Med Chem Lett 2007;17:4026-9
   PubMed Web of Science ®Google Scholar
• Meyer GE, Chesler L, Liu D, Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells. J Cell Biochem 2007;102:1529-41
   PubMed Web of Science ®Google Scholar
• Youngren JF, Gable K, Penaranda C, Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 2005;94:37-46
   PubMed Web of Science ®Google Scholar
• Zavodovskaya M, Campbell MJ, Maddux BA, Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells. J Cell Biochem 2008;103:624-35
   PubMed Web of Science ®Google Scholar
• Britten C, Smith DC, Bui LA, A Phase I Dose-Escalation Study of XL228, a Potent IGF-1R / SRC / Aurora Inhibitor, in Patients with Advanced Malignancies. AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, Discovery, Biology, and Clinical Applications 2008; Eur J Cancer 2008;6(12): abstract #390
   Google Scholar
• Smith DC, Britten C, Clary DO, A phase I study of XL228, a potent IGF1R/AURORA/SRC inhibitor, in patients with solid tumors or hematologic malignancies. J Clin Oncol 2009;27(15s): abstract #3512
   Google Scholar
• Gualberto A, Hixon ML, Karp DD, Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 2011;104:68-74
   PubMed Web of Science ®Google Scholar
• Gualberto A, Dolled-Filhart M, Gustavson M, Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res;16:4654-65
   PubMed Web of Science ®Google Scholar
• Pitts TM, Tan AC, Kulikowski GN, Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res 2010;16:3193-3204
   PubMed Web of Science ®Google Scholar
• Ravenel JD, Broman KW, Perlman EJ, Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms tumor. J Natl Cancer Inst 2001;93:1698-703
   PubMed Web of Science ®Google Scholar
• Xu W, Fan H, He X, LOI of IGF2 is associated with esophageal cancer and linked to methylation status of IGF2 DMR. J Exp Clin Cancer Res 2006;25:543-7
   PubMed Web of Science ®Google Scholar
• Zhan S, Shapiro DN, Helman LJ. Loss of imprinting of IGF2 in Ewing's sarcoma. Oncogene 1995;11:2503-7
   PubMed Web of Science ®Google Scholar
• Li Y, Meng G, Huang L, Guo QN. Hypomethylation of the P3 promoter is associated with up-regulation of IGF2 expression in human osteosarcoma. Hum Pathol 2009;40:1441-7
   PubMed Web of Science ®Google Scholar
• Fu VX, Dobosy JR, Desotelle JA, Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate. Cancer Res 2008;68:6797-802
   PubMed Web of Science ®Google Scholar
• Wu J, Qin Y, Li B, Hypomethylated and hypermethylated profiles of H19DMR are associated with the aberrant imprinting of IGF2 and H19 in human hepatocellular carcinoma. Genomics 2008;91:443-50
   PubMed Web of Science ®Google Scholar